European Archives of Oto-Rhino-Laryngology

, Volume 267, Issue 4, pp 483–494

Assay-based response evaluation in head and neck oncology: requirements for better decision making

  • Andreas Dietz
  • Andreas Boehm
  • Iris-Susanne Horn
  • Pierre Kruber
  • Ingo Bechmann
  • Wojciech Golusinski
  • Dietger Niederwieser
  • Ralph Dollner
  • Torsten W. Remmerbach
  • Christian Wittekind
  • Stephan Dietzsch
  • Guido Hildebrandt
  • Gunnar Wichmann
Review Article


This article gives an overview on different current strategies of assay-based response evaluation in head and neck squamous cell carcinomas (HNSCC) and critically summarizes their role and needs for future clinical evaluation. Due to a growing amount of data of phase III clinical trials of multimodality treatment options for HNSCC, treatment planning in regard to optimal outcome is becoming an interdisciplinary challenge. New concepts such as induction chemotherapy with bi- or ternary combinations of chemotherapeutics, integration of targeted therapies, concurrent and sequential chemoradiation concepts, and multimodality-based organ preservation strategies strongly compete with traditional definitive surgical procedures. Moreover, the outcome is difficult to predict due to heterogeneity of a tumor’s response, impaired late functional outcome, and increased late toxicity if simultaneously applied to radiation. Retrospectively looking at non-responders with tumors classified as resectable, primary surgery is very likely to have achieved better results, since chemoradiation causes a high degree of early and late toxicities leading to extremely complicated terms and conditions in surgery following current multimodal therapeutic strategies. Unfortunately, predictive information on response characteristics of a given tumor before starting the therapy is not available in daily routine, although heterogeneity in response of a given tumor entity to treatments has been known for decades. Therefore, current therapy strategies for HNSCC still have to ignore this fact, creating an urgent need for the development of proper predictive assays. There are interesting clinical observations showing that response on induction chemotherapy may predict the outcome after radiotherapy. Some trials use this empiric phenomenon to pre-select non-responders for primary surgical treatment avoiding severe salvage complications after failure of complete chemoradiation treatment. Moving one step further, recent literature and our own investigations implicate that response evaluation of the individual patient’s HNSCC in a suitable ex vivo assay just before starting the treatment is mature for clinical research. To this end, essential needs and hints are addressed and discussed.


Clonogenic assay FLAVINO-assay Response evaluation HNSCC Chemosensitivity testing Head and neck cancer 


  1. 1.
    Biorklund A, Hakansson L, Stenstan B, Trope C, Akerman M (1980) Heterogeneity of non-Hodkin’s lymphomas as regards sensitivity to cytostatic drugs. An in vitro study. Eur J Cancer 16:647–654PubMedGoogle Scholar
  2. 2.
    Castro M (2005) Resisting a fundamentalist policy. J Clin Oncol 23:3645–3646CrossRefPubMedGoogle Scholar
  3. 3.
    Cheng SH, Lam W, Lee ASK, Fung KP, Wu RSS, Fong WF (2000) Low-level doxorubicin resistance in benzo(a)pyrene-treated KB-3–1 cells is associated with increased LRP expression and altered subcellular drug distribution. Toxicol Appl Pharmacol 164:134–142CrossRefPubMedGoogle Scholar
  4. 4.
    Cree IA (2009) Chemosensitivity and chemoresistance testing in ovarian cancer. Curr Opin Obstet Gynecol 21(1):39–43CrossRefPubMedGoogle Scholar
  5. 5.
    Danks MK, Yalowich JC, Beck WT (1987) Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res 47:1297–1301PubMedGoogle Scholar
  6. 6.
    Dietz A, Rudat V, Dreyhaupt J, Pritsch M, Hoppe F, Hagen R, Pfreundner L, Schröder U, Eckel H, Hess M, Schröder M, Schneider P, Jens B, Zenner HP, Werner JA, Engenhardt-Cabillic R, Vanselow B, Plinkert P, Niewald M, Kuhnt T, Budach W, Flentje M (2009) Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial). Eur Arch Otorhinolaryngol 266(8):1291–1300CrossRefPubMedGoogle Scholar
  7. 7.
    Dietz A, Boehm A, Mozet C, Wichmann G, Giannis A (2008) Current aspects of targeted therapy in head and neck tumors. Eur Arch Otorhinolaryngol 265(Suppl 1):3–12CrossRefGoogle Scholar
  8. 8.
    Dietz A, Tschöp K, Wichmann G, Granzow C (2008) Method and kit for the ex vivo evaluation of the response of a tumor to conditions to be tested. US-Provisional Ser. No. 61/044,082Google Scholar
  9. 9.
    Dollner R, Granzow C, Neudert M, Dietz A (2006) Ex vivo chemosensitivity of head and neck carcinoma to cytostatic drug combinations. Anticancer Res 26:1651–1655PubMedGoogle Scholar
  10. 10.
    Dollner R, Granzow C, Werner JA, Dietz A (2004) Is there a role for chemosensitivity tests in head and neck cancer? Onkologie 27(3):310–315CrossRefPubMedGoogle Scholar
  11. 11.
    Dollner R, Kopun M, Dietz A, Wiessler M, Granzow C (2002) Chemoreactivity profiling of HNSCC: Equipotentiality of platinum compounds and glufosfamide, a novel alkylating agent. Proc Am Assoc Cancer Res 43:926Google Scholar
  12. 12.
    Dollner R, Granzow C, Helmke BM, Ruess A, Schad A, Dietz A (2004) The impact of stromal cell contamination on chemosensitivity testing of head and neck carcinoma. Anticancer Res 24:325–331PubMedGoogle Scholar
  13. 13.
    Dollner R, Ruess A, Granzow C, Dietz A (2004) Reevaluation of the pharmacological microheterogeneity of head and neck squamous cell carcinoma in ex-vivo chemosensitivity tests. Eur Arch Otorhinolaryngol 261:350–356Google Scholar
  14. 14.
    Elprana D, Schwachofer J, Kuijpers W, van den Broek P, Wagener DJ (1987) In vitro chemosensitivity testing of squamous cell carcinoma of the head neck. Acta Otolaryngol 103:529–536PubMedGoogle Scholar
  15. 15.
    Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098CrossRefPubMedGoogle Scholar
  16. 16.
    Fruehauf JP (2002) In vitro assay-assisted treatment selection for women with breast or ovarian cancer. Endocr Relat Cancer 9:171–182CrossRefPubMedGoogle Scholar
  17. 17.
    Gallion H, Christopherson WA, Coleman RL, DeMars L, Herzog T, Hosford S, Schellhas H, Wells A, Sevin BU (2006) Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 16:194–201CrossRefPubMedGoogle Scholar
  18. 18.
    Gazdar AF, Steinberg SM, Russell EK, Linnoila RI, Oie HK, Ghosh BC, Cotelingam JD, Johnson BE, Minna JD, Ihde DC (1990) Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. J Natl Cancer Inst 82:117–124CrossRefPubMedGoogle Scholar
  19. 19.
    Gey GO, Coffman WD, Kubicek MT (1952) Tissue culture studies of the proliferative capacity of cervical carcinoma and normal epithelium. Cancer Res 12:264–265Google Scholar
  20. 20.
    Glinsky GV (2008) Stemness’ genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol 26:2846–2853CrossRefPubMedGoogle Scholar
  21. 21.
    Granzow C, Kopun M, Kröber T (1995) Riboflavin-mediated photosensitization of Vinca alkaloids distorts drug sensitivity assays. Cancer Res 55:4837–4843PubMedGoogle Scholar
  22. 22.
    Granzow C, Kopun M, Heuser M, Herth F, Becker HD (2004) Chemoresistance of human lung tumor stromal cells. Am Assoc Cancer Res 95th Annual Meeting Proc Suppl abstract LB-82Google Scholar
  23. 23.
    Grzelak A, Rychlik B, Bartosz G (2001) Light-dependent generation of reactive oxygen species in cell culture media. Free Rad Biol Med 30:1418–1425CrossRefPubMedGoogle Scholar
  24. 24.
    Hamburger AW, Salmon SE (1977) Primary bioassay of human tumor stem cells. Science 197:461–463CrossRefPubMedGoogle Scholar
  25. 25.
    Hasegawa Y, Goto M, Hanai N, Ijichi K, Adachi M, Terada A, Hyodo I, Ogawa T, Furukawa T (2007) Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer. Oral Oncol 43:749–756CrossRefPubMedGoogle Scholar
  26. 26.
    Heuser M, Kopun M, Rittgen W, Granzow C (2005) Cytotoxicity determination without photochemical artifacts. Cancer Lett 223:57–66CrossRefPubMedGoogle Scholar
  27. 27.
    Higgins KM, Wang JR (2008) State of head and neck surgical oncology research–a review and critical appraisal of landmark studies. Head Neck 30(12):1636–1642CrossRefPubMedGoogle Scholar
  28. 28.
    von Hoff DD (1990) He’s not going to talk about in vitro predictive assay again, is he? J Natl Cancer Inst 82:96–101CrossRefGoogle Scholar
  29. 29.
    Von Hoff DD, Clark GM, Stogdill BJ, Sarosdy MF, O’Brien MT, Casper JT, Mattox DE, Page CP, Cruz AB, Sandbach JF (1983) Prospective clinical trial of a human tumor cloning system. Cancer Res 43:1926–1931Google Scholar
  30. 30.
    Hoffmann TK, Sonkoly E, Hauser U, Lierop A, Whiteside TL, Klussmann JP, Hafner D, Schuler P, Friebe-Hoffmann U, Scheckenbach K, Erjala K, Gréman R, Schipper J, Bier H, Balz V (2008) Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral Oncol 44(12):1100–1109CrossRefPubMedGoogle Scholar
  31. 31.
    Hoffman RM (1991) In vitro sensitvity assays in cancer: A review, analysis, and prognosis. J Clin Lab Anal 5:133–143CrossRefPubMedGoogle Scholar
  32. 32.
    Hofmann V, Holdener EE, Müller M, Früh (1984) Interlaboratory comparison of in vitro cloning of fresh human tumor cells from malignant effussions Recent Results. Cancer Res 94:197–201Google Scholar
  33. 33.
    Horn IS, Wichmann G, Mozet C, Dietz A, Dollner R, Tschöp K, Boehm A (2009) Heterogeneity of epithelial and stromal cells of head and neck squamous cell carcinomas in ex-vivo chemoresponse. Chemotherapy Sept 22. [E-pub ahead of print]Google Scholar
  34. 34.
    Johns ME, Mills SE, Thompson KK (1983) Colony-forming assay of human salivary gland tumors. Applications for chemosensitivity and histogenetic studies. Arch Otolaryngol 109:709–714PubMedGoogle Scholar
  35. 35.
    Juvekar AS, Amonkar AJ, D’cruz AK, Saikaia T, Pradhan S (1998) Chemosensitivity of advanced larynx carcinoma cells in vitro and significance of multidrug resistance markers in these tumors. Cancer Biother Radiopharm 13:81–87CrossRefPubMedGoogle Scholar
  36. 36.
    Kern DH, Drogemuller CR, Kennedy MC, Hildebrand-Zanki SU, Tanigawa N, Sondak VK (1985) Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors. Cancer Res 45:5436–5441PubMedGoogle Scholar
  37. 37.
    Kern DH, Weisenthal LM (1990) Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 82:582–588CrossRefPubMedGoogle Scholar
  38. 38.
    Kurbacher CM, Cree IA, Bruckner HW, Brenne U, Kurbacher JA, Müller K, Ackermann T, Gilster TJ, Wilhelm LM, Engel H, Mallmann PK, Andreotti PE (1998) Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs 9:51–57CrossRefPubMedGoogle Scholar
  39. 39.
    Kusumoto T, Sakaguchi Y, Maehra Y, Nakashima T, Furusawa M, Sugimachi K (1992) Comparison of in vitro anticancer chemosensitivity between human squamous cell carcinoma and adenocarcinoma. Oncology 49:343–346CrossRefPubMedGoogle Scholar
  40. 40.
    Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T (1996) Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:890–899CrossRefPubMedGoogle Scholar
  41. 41.
    Lefebvre JL, Ang KK (2009) Larynx Preservation Consensus Panel. Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary. Int J Radiat Oncol Biol Phys 73(5):1293–1303PubMedGoogle Scholar
  42. 42.
    Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, Forastiere A, Ang KK (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26(21):3582–9Google Scholar
  43. 43.
    Maenpaa JU, Heinonen E, Hinkka SM, Karnani P, Klemi PJ, Korpijaakko TA, Kuoppala TA, Laine AM, Lähde MA, Nuoranne EK (1995) The subrenal capsule assay in selecting chemotherapy for ovarian cancer: A prospective randomized trial. Gynecol Oncol 57:294–298CrossRefPubMedGoogle Scholar
  44. 44.
    Marquardt F, Rödel F, Capalbo G, Weiss C, Rödel C (2009) Molecular targeted treatment and radiation therapy for rectal cancer. Strahlenther Onkol 185(6):371–378CrossRefPubMedGoogle Scholar
  45. 45.
    Master JRW (2000) Human cancer cell lines: fact and fantasy. Nature Rev Mol Cell Biol 1:233–236CrossRefGoogle Scholar
  46. 46.
    Mattox DE, von Hoff DD (1980) In vitro stem cell assay in head and neck squamous carcinoma. Am J Surg 140:527–530CrossRefPubMedGoogle Scholar
  47. 47.
    Michalski CW, Erkan M, Sauliunaite D, Giese T, Stratmann R, Sartori C, Giese NA, Friess H, Kleeff J (2008) Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer 99(5):760–767CrossRefPubMedGoogle Scholar
  48. 48.
    Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H, Tashiro S (2004) Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 28:38–44CrossRefPubMedGoogle Scholar
  49. 49.
    Mukaida H, Hirabayashi N, Hirai T, Iwata T, Saeki S, Toge T (1991) Sigificance of freshly cultured fibroblasts from different tissues in promoting cancer cell growth. Int J Cancer 48:423–427CrossRefPubMedGoogle Scholar
  50. 50.
    Nakashima T, Maehra Y, Kohnoe S, Hayashi I, Katsuta Y (1990) Histologic differentiation and chemosensitivity of human head and neck squamous cell carcinoma. Head Neck 12:406–410CrossRefPubMedGoogle Scholar
  51. 51.
    Neubauer H, Stefanova M, Solomayer E, Meisner C, Zwirner M, Wallwiener D, Fehm T (2008) Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Anticancer Res 28:949–955PubMedGoogle Scholar
  52. 52.
    Nitsch R, Bechmann I, Deisz RA, Haas D, Lehmann TN, Wendling U, Zipp F (2000) Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) Lancet 356(9232):827–8Google Scholar
  53. 53.
    Okumura H, Chen ZS, Sakou M, Sumizawa T, Furukawa TKM (2000) Reversal of P-glycoprotein and multidrug-resistance protein-mediated drug resistance in KB cells by 5-O-benzoylated taxinine K. Mol Pharmacol 58:1563–1569PubMedGoogle Scholar
  54. 54.
    Pfreundner L, Hoppe F, Willner J, Preisler V, Bratengeier K, Hagen R, Helms J, Flentje M (2003) Induction chemotherapy with paclitaxel and cisplatin and CT-based 3D radiotherapy in patients with advanced laryngeal and hypopharyngeal carcinomas—a possibility for organ preservation. Radiother Oncol 68:163–170CrossRefPubMedGoogle Scholar
  55. 55.
    Pignon JP, le Maître A, Maillard E, Bourhis J (2009) MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92(1):4–14CrossRefPubMedGoogle Scholar
  56. 56.
    Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M, Calais G (2009) Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101(7):498–506Google Scholar
  57. 57.
    Reimers N, Kasper HU, Weissenborn SJ, Stützer H, Preuss SF, Hoffmann TK, Speel EJ, Dienes HP, Pfister HJ, Guntinas-Lichius O, Klussmann JP (2007) Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 120:1731–1738CrossRefPubMedGoogle Scholar
  58. 58.
    Riou JF, Naudin A, Lavelle F (1992) Effects of taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 187:164–170CrossRefPubMedGoogle Scholar
  59. 59.
    Robbins KT, Shaha AR, Medina JE, Califano JA, Wolf GT, Ferlito A, Som PM, Day TA (2008) Committee for Neck Dissection Classification, American Head and Neck Society. Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg 134(5):536–538CrossRefPubMedGoogle Scholar
  60. 60.
    Robbins KT, Varki NM, Storniolo AM, Hoffman H, Hoffman RM (1991) Drug response of head and neck tumors in native-state histoculture. Arch Otolaryngol Head Neck Surg 117:83–86PubMedGoogle Scholar
  61. 61.
    Rosenthal EL, McCrory A, Talbert M, Carroll W, Magnuson JS, Peters GE (2004) Expression of proteolytic enzymes in head and neck cancer-associated fibroblasts. Arch Otolaryngol Head Nack Surg 130:943–947CrossRefGoogle Scholar
  62. 62.
    Rudat V, Eckel H, Volling P, Schröder M, Staar S, Wallner F, Wannenmacher M, Dietz A (2008) Long-term results of a prospective multicenter phase II study to preserve the larynx function using concomitant boost radiochemotherapy with Carboplatin. Radiother Oncol 89(1):33–37CrossRefPubMedGoogle Scholar
  63. 63.
    Santillan A, Kim YW, Zahurak ML, Gardner GJ, Giuntoli RL 2nd, Shih IM, Bristow RE (2007) Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma. Int J Gynecol Cancer 17:601–606CrossRefPubMedGoogle Scholar
  64. 64.
    Schlag P, Flentje D (1984) Chemosensitivity testing of human neoplasms using the soft agar colony assay. Cancer Treat Rev 11:131–137CrossRefPubMedGoogle Scholar
  65. 65.
    Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR (2004) ASCO Working Group on Chemotherapy Sensitivity and Resistance Assays. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 22(17):3631–3638CrossRefPubMedGoogle Scholar
  66. 66.
    Schroyens W, Tueni E, Dodion P, Bodecker R, Stoessel F, Klastersky J (1990) Validation of clinical predictive value of in vitro colorimetric chemosensitivity assay in head and neck cancer. Eur J Cancer 26:834–838CrossRefPubMedGoogle Scholar
  67. 67.
    Shah JP, Patel SG Ed. (2003) Head and neck surgery and oncology, Feb Mosby Ltd. ISBN: 0723432236Google Scholar
  68. 68.
    Shaw GL, Gazdar AF, Phelps R, Steinberg SM, Linnoila RI, Johnson BE, Oie HK, Russell EK, Ghosh BC, Pass HI, Minna JD, Mulshine JL, Ihde DC (1996) Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem Suppl 24:173–185CrossRefPubMedGoogle Scholar
  69. 69.
    Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Goberdhan A, Hoffman RM, Shah J (2002) Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 24:437–442CrossRefPubMedGoogle Scholar
  70. 70.
    Song Z, Powell WC, Kasahara N, van Bokhoven A, Miller GJ, Roy-Burman P (2000) The effect of fibroblast growth factor 8, isoform b, on the biology of prostata carcinoma cells and their interaction with stromal cells. Cancer Res 60:6730–6736PubMedGoogle Scholar
  71. 71.
    Stausbøl-Grøn B, Nielsen OS, Beten SM, Overgaard J (1995) Selective assessment of in vitro radiosensitivity of tumour cells and fibroblasts from single tumour biopsies using immunocytochemical identification of colonies in the soft agar clonogenic assay. Radiother Oncol 37:87–99CrossRefPubMedGoogle Scholar
  72. 72.
    Tanigawa N, Mizuno YHT, Hashimura T, Honda K, Satomura K, Hikasa Y, Niwa O, Sugahar T, Yoshida O, Kern DH, Morton DL (1984) Comparison of drug sensitivity among tumor cells within a tumor, between primary tumor and metastases, and between different metastases in the human tumor colony- forming assay. Cancer Res 44:2309–2312PubMedGoogle Scholar
  73. 73.
    The Department of Veterans Affairs Laryngeal Cancer Study Group (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324:1685–1690CrossRefGoogle Scholar
  74. 74.
    Volpato M, Phillips RM (2007) Tailoring targeted therapy to individual patients: lessons to be learned from the development of mitomycin C Cancer Genomics Proteomics 4 (3):175–186Google Scholar
  75. 75.
    Wilbur DW, Camacho ES, Hilliard DA, Dill PL, Weisenthal LM (1992) Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measuring total tumour cell kill. Br J Cancer 65:27–32PubMedGoogle Scholar
  76. 76.
    Wichmann G, Horn I-S, Boehm A, Mozet C, Tschöp K, Dollner R, Dietz A (2009) Single biopsies from head and neck squamous cell carcinomas are representative regarding the entire tumor’s chemosensitivity to cisplatin and docetaxel. Onkologie 32(5):264–272CrossRefPubMedGoogle Scholar
  77. 77.
    Wittekind C, Compton C, Quirke P, Nagtegaal I, Merkel S, Hermanek P, Sobin LH (2009) A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status. Cancer 115(15):3483–3488CrossRefPubMedGoogle Scholar
  78. 78.
    Wu KY, Wang HZ, Hong SJ (2008) Mechanism of mitomycin-induced apoptosis in cultured corneal endothelial cells. Mol Vis 14:1705–1712PubMedGoogle Scholar
  79. 79.
    Yanagisawa T, Urade M, Takahashi Y, Kishimoto H, Sakurai K (1998) Isolation and characterization of radioresistant human KB carcinoma cells in vitro. Oral Oncol 34:30–38CrossRefPubMedGoogle Scholar
  80. 80.
    Yusa K, Sato W, Yamazaki A, Tsukahara S, Tsuruo T (1991) Cross-resistance of human multidrug-resistant cells to mitomycin C. Anticancer Res 11:1301–1304PubMedGoogle Scholar
  81. 81.
    Zhang S, Balch C, Chan MW (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68:4311–4320CrossRefPubMedGoogle Scholar
  82. 82.
    Zeng Y, Kulkarni P, Inoue T, Getzenberg RH (2009) Down-regulating cold shock protein impairs cancer cell survival and enhances chemosensitivity J Cell Biochem 107(1):179–188Google Scholar
  83. 83.
    Zhang W, Matrisian LM, Holmbeck K, Vick CC, Rosenthal EL (2006) Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer 6:52–58CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Andreas Dietz
    • 1
    • 10
  • Andreas Boehm
    • 1
  • Iris-Susanne Horn
    • 1
  • Pierre Kruber
    • 1
  • Ingo Bechmann
    • 2
  • Wojciech Golusinski
    • 3
  • Dietger Niederwieser
    • 4
  • Ralph Dollner
    • 5
  • Torsten W. Remmerbach
    • 6
  • Christian Wittekind
    • 7
  • Stephan Dietzsch
    • 8
  • Guido Hildebrandt
    • 9
  • Gunnar Wichmann
    • 1
  1. 1.Department of Otolaryngology, Head and Neck SurgeryUniversity Clinic of LeipzigLeipzigGermany
  2. 2.Institute of AnatomyUniversity Clinic of LeipzigLeipzigGermany
  3. 3.Head and Neck DepartmentGreat Poland Cancer CenterPoznanPoland
  4. 4.Department of Hematology and OncologyUniversity Clinic of LeipzigLeipzigGermany
  5. 5.Department of Otorhinolaryngology, Head and Neck Surgery, RikshospitaletOslo University HospitalOsloNorway
  6. 6.Department of Maxillo Facial SurgeryUniversity Clinic of LeipzigLeipzigGermany
  7. 7.Institute of PathologyUniversity Clinic of LeipzigLeipzigGermany
  8. 8.Institute of RadiooncologyUniversity Clinic of LeipzigLeipzigGermany
  9. 9.Institute of RadiooncologyUniversity Clinic of RostockRostockGermany
  10. 10.Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde/Plastische OperationenUniversität LeipzigLeipzigGermany

Personalised recommendations